News Headline Summary

Teva (TEVA) says superior patient outcomes compared with current studies support B-R combo as first line for lymphomas

Says:
- Reports significantly prolonged progression free survival.
- Reports significantly prolonged overall survival.
- Says B-R combo shows superior patient outcomes vs standard.

Print 12:36, 11 Dec 2012 - US Equities - Source: Newswires